<DOC>
	<DOCNO>NCT02954978</DOCNO>
	<brief_summary>Parkinson 's disease ( PD ) second common neurodegenerative disorder cause motor non-motor symptom . PD characterize death dopaminergic ( DA ) neuron substantia nigra ( SN ) par compacta formation inclusion know Lewy body ( LBs ) primarily contain aggregated alpha-Synuclein . Nilotinib ( Tasigna® , AMN107 , Novartis , Switzerland ) approve U.S. Food Drug Administration ( FDA ) well tolerate CML treatment oral dose 600-800mg daily . Nilotinib penetrate brain promotes autophagic degradation alpha-Synuclein p-Tau , lead survival DA neuron improvement motor function PD model . For study , Nilotinib ( 1-10mg/kg daily ) use significantly less clinically approve dose ( 1200mg daily ) CML .</brief_summary>
	<brief_title>Impact Nilotinib Safety , Tolerability , Pharmacokinetics Biomarkers Parkinson 's Disease</brief_title>
	<detailed_description>Based strong pre-clinical evidence effect Nilotinib neurodegenerative pathology , include autophagic clearance neurotoxic protein , neurotransmitter ( dopamine glutamate ) , immunity behavior , investigator conduct open label pilot clinical trial advance PD dementia ( PDD ) Dementia Lewy Body ( DLB ) ( stage 3-4 ) patient . Participants ( N=12 ) randomize 1:1 daily oral dose 150mg 300mg Nilotinib 6 month . The investigator ' data suggest Nilotinib penetrates brain inhibits CSF Abelson ( Abl ) activity via reduction phosphorylated Abl agreement pre-clinical data . Several study show CSF alpha-Synuclein Abeta42 decrease CSF total Tau p-Tau increase PD DLB . The investigator ' data show attenuation loss CSF alpha-Synuclein Abeta40/42 300mg ( 50 % CML dose ) compare 150mg Nilotinib 6 month treatment . CSF homovanillic acid ( HVA ) , end by-product dopamine , significantly increase ; CSF total Tau p-Tau significantly reduce ( N=5 , P &lt; 0.05 ) 300mg Nilotinib baseline 6 month treatment . Despite reduction L-Dopa replacement therapy study , UDPRS I-IV score improve 150mg ( 3.5 point ) 300mg ( 11 point ) baseline 6 month worsen ( 13.7 point 11.4 point ) 3 month withdrawal 150mg 300mg , respectively . Other non-motor function e.g . constipation resolve patient cognition also improve ( 3.5 point ) use Mini-Mental Status Exam ( MMSE ) Scales Outcomes Parkinson 's Disease-Cognition ( SCOPA-Cog ) baseline 6 month . MMSE score return baseline 3 month Nilotinib withdrawal . These data compel evaluate effect Nilotinib phase II , randomize , double-blind , placebo-controlled trial patient PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>1 . Written inform consent 2 . Capable provide informed consent comply study procedure . Subjects unable provide consent may use Legally Authorized Representative ( LAR ) . 3 . Patients age 4090 year , medically stable 4 . Diagnosis PD accord UK Brain Bank Diagnostic Criteria 5 . PD subject MoCA ≥ 22 6 . 2.5 ≥Hoehn Yahr stage ≤3 7 . No monoamine oxidase ( MAO ) B inhibitor ( Selegeline rasagiline ) allow least 6 week enrollment 8 . Must medically stable 800mg Levodopa daily least 4 week 9 . QTc interval 350460 m , inclusive 10 . Participants must willing undergo LP baseline 12 month treatment 1 . Patients hypokalemia , hypomagnesaemia , long QT syndrome QTc≥461 ms 2 . Concomitant drug know prolong QTc interval history cardiovascular disease , include myocardial infraction cardiac failure , angina , arrhythmia 3 . History presence cardiac condition include : Cardiovascular cerebrovascular event ( e.g . myocardial infarction , unstable angina , stroke ) Congestive heart failure First , second thirddegree atrioventricular block , sick sinus syndrome , serious cardiac rhythm disturbance Any history Torsade de Pointes 4 . Treatment follow drug time screen precede 30 day , and/or plan use course trial : Treatment Class IA III antiarrhythmic drug ( e.g . quinidine ) Treatment QT prolong drug ( www.crediblemeds.org ) exclude Selective Serotonin Reuptake Inhibitors ( SSRIs ) ( e.g . Citalopram , Paxil , Zoloft , Cymbalta , Sertraline , etc ... ) Strong CYP3A4 inhibitor ( include grapefruit juice ) . The concomitant use strong CYP3A4 inhibitor ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole ) must avoid . Grapefruit product may also increase serum concentration Nilotinib . Should treatment agent require , therapy Nilotinib interrupt . Anticoagulants , include Coumadin ( warfarin ) , heparin , enoxaparin , daltiparin , xarelto , etc . St. John 's Wort concomitant use strong CYP3A4 inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital ) must avoid since agent may reduce concentration Nilotinib . 5 . Abnormal liver function define AST and/or ALT &gt; 100 % upper limit normal 6 . Renal insufficiency define serum creatinine &gt; 1.5 time upper limit normal 7 . History HIV , clinically significant chronic hepatitis , active infection 8 . Females must lactate , pregnant possible pregnancy 9 . Medical history liver pancreatic disease 10 . Clinical sign indicate syndrome idiopathic PD , include corticobasal degeneration , supranuclear gaze palsy , multiple system atrophy , chronic traumatic encephalopathy , sign frontal dementia , history stroke , head injury encephalitis , cerebellar sign , early severe autonomic involvement , Babinski sign 11 . Current evidence history past two year epilepsy , focal brain lesion , head injury loss consciousness DSMIV criterion major psychiatric disorder include psychosis , major depression , bipolar disorder , alcohol substance abuse 12 . Evidence significant clinical disorder laboratory find render participant unsuitable receive investigational drug include clinically significant unstable hematologic , hepatic , cardiovascular , pulmonary , gastrointestinal , endocrine , metabolic , renal systemic disease laboratory abnormality 13 . Active neoplastic disease , history cancer five year prior screen , include breast cancer ( history skin melanoma stable prostate cancer exclusionary ) 14 . Contraindications LP : prior lumbosacral spine surgery , severe degenerative joint disease deformity spine , platelet &lt; 100,000 , use Coumadin/warfarin , history bleed disorder 15 . Must immunosuppressant medication ( e.g . IVig ) 16 . Must enrol active participant another clinical study 17 . Diagnosis DLB</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>